Michael Kelly is an experienced Oncology Therapeutic Specialist at Incyte since January 2018, focusing on Jakafi (ruxolitinib) and Pemazyre (pemigatinib) across various esteemed medical centers and community oncology practices, with a specialization in hematology, particularly myeloproliferative neoplasms and GVHD. Previously, Michael served as a Hematology Clinical Account Specialist at Pharmacyclics, where responsibilities included promoting Imbruvica for CLL and lymphoma within numerous healthcare facilities. Michael's extensive background also includes a decade as a Senior Clinical Oncology Specialist at Genentech, where the role encompassed multiple oncology drugs in diverse cancer types, including immune-mediated and lung cancers. Education includes a Bachelor's degree in Psychology from the University of California Santa Barbara.
This person is not in the org chart
This person is not in any teams
This person is not in any offices